TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00133575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).
Study: NCT00004088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study: NCT00133575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
Study: NCT00004088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT00133575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
Study: NCT00004088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate disodium
Study: NCT00133575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
Study: NCT04157933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-A1
Description: Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-A2
Description: Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-A3
Description: Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 009-A0
Description: Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-B1 (active --> placebo) crossover
Description: Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-B2 (placebo --> active) crossover
Description: Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
Study: NCT00004088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01047124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialist Mood Disorders Team
Description: The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
Study: NCT03121794

Intervention type: PROCEDURE
Intervention: Ultrasonographic exam
Description: The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks

Intervention type: PROCEDURE
Intervention: Ultrasonographic exam
Description: The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks

Intervention type: PROCEDURE
Intervention: Ultrasonographic exam
Description: The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
Study: NCT03040947

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Study: NCT02264782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Complete PreView

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention
Description: Watch an educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03893747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
Description: 500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
Description: 500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
Description: 500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
Description: 500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
Description: 500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
Description: 500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
Study: NCT00645580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine 100mg/day PO for 6 weeks.
Study: NCT04500028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 vaginal tablet of isonicotinic acid hydrazide (900mg) inserted by the study nurse 4 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 3 tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
Study: NCT02191904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes
Study: NCT03432390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open system ventilation
Description: Facemask ventilation adapted to the anesthesia work station
Study: NCT01510353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation monitoring device
Description: Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
Study: NCT05311553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zona pellucida thinning
Description: Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zona pellucida drilling
Description: Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.
Study: NCT02297685

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous nerve stimulation
Description: The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Description: The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential currents
Description: The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
Study: NCT02768350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation technique
Description: Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
Study: NCT03720223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: 20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
Study: NCT04810897

Intervention type: OTHER
Intervention: Exercise
Description: Exercise programme is reported in the clinical trial registration number is NCT03473834.
Study: NCT02777645

Intervention type: OTHER
Intervention: Growth, feeding evaluation
Description: Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions

Intervention type: OTHER
Intervention: Growth, feeding evaluation
Description: Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
Study: NCT02802397

Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered questionnaire and blood and urine samples
Description: Self-administered questionnaire and blood and urine samples

Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered questionnaire and blood and urine samples
Description: Self-administered questionnaire and blood and urine samples
Study: NCT02961478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOHEXOL
Description: Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
Study: NCT01115608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist follow-up
Description: Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
Study: NCT01850030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 30 mg
Description: Oral Dydrogesterone 10 mg tablets tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone 600 mg
Description: Intravaginal micronized progesterone 200 mg capsules tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo progesterone
Description: Placebo intravaginal micronized progesterone 200 mg capsules tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo dydrogesterone
Description: placebo oral dydrogesterone 10 mg tablets tid
Study: NCT04201145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV, predetermined dosage, twice per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV, predetermined dosage, twice per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV, predetermined dosage, twice per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV, predetermined dosage, twice per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort
Study: NCT04211389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-151 0.3% cream
Description: ARQ-151 0.3% cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-151 vehicle cream
Description: ARQ-151 vehicle cream
Study: NCT04678778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and Cognitive Activity
Description: There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
Study: NCT00831077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORM-14540
Description: i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORM-12741
Description: i.v.
Study: NCT01348152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAIKENCHUTO (TU-100)
Description: Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
Study: NCT04107753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling based on the 5As model
Description: It is a structured brief counselling perfomed by nurse who takes clinical care of the patient and it is performed as follow:~1. ASK: every patient should be asked whether he/she is or is not a smoker;~2. ADVICE: the patient is advised to quit in a strong, clear and personalized way;~3. ASSESS: the patient is asked if he/she would like to quit and the strenght of his/her dependence is assessed.~4. ASSIST: The smoker interested in quitting are assisted in their attempts, for example by helping them to define a quit date, by advising them about strategies against withdrawal symptoms and by providing them information material; patients are asked whether they want to be contacted by the CTT.~5. ARRANGE: this step is only addressed to the patients who have started a treatment in the CTT and is expected to prevent or treat eventual relapses.
Study: NCT03062696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-RD
Description: 5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
Study: NCT02001142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: single session of exercise
Study: NCT04402697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention
Description: OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention
Description: OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling.
Study: NCT05608031

Intervention type: OTHER
Intervention: Pittsburgh sleep quality index (PSQI) scale
Description: Pittsburgh Sleep Quality Index (PSQI) (6), a self-report questionnaire comprising seven component scores (subjective sleep quality, sleep latency, duration of sleep, sleep efficiency habits, sleep disturbances, use of sleeping medication, and daytime dysfunction), was used to evaluate sleep quality over the last month.
Study: NCT01081275

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CI Therapy
Description: CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAM treatments
Description: CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
Study: NCT01337206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting with ELLA Biodegradable stent
Description: Treating benign esophageal lesions with the placement of a degradable stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dilations
Description: Treating benign esophageal lesions with standard dilation therapy
Study: NCT02737423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Effect of Vitamin D on the symptoms of diabetic neuropathy
Study: NCT04206085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve - Active
Description: Radiofrequency and Cryogen-Cooling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viveve - Cryogen-Alone
Description: Cryogen-Cooling

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Viveve - Sham
Description: Sham